Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $242.5 million.

  • Ironwood Pharmaceuticals' Total Current Liabilities rose 39106.58% to $242.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $242.5 million, marking a year-over-year increase of 39106.58%. This contributed to the annual value of $38.8 million for FY2024, which is 8593.05% down from last year.
  • Ironwood Pharmaceuticals' Total Current Liabilities amounted to $242.5 million in Q3 2025, which was up 39106.58% from $232.5 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Total Current Liabilities high stood at $305.4 million for Q2 2023, and its period low was $23.3 million during Q2 2022.
  • For the 5-year period, Ironwood Pharmaceuticals' Total Current Liabilities averaged around $130.7 million, with its median value being $134.4 million (2021).
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Total Current Liabilities surged by 121079.92% in 2023, and later crashed by 8593.05% in 2024.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Total Current Liabilities stood at $161.7 million in 2021, then plummeted by 84.21% to $25.5 million in 2022, then soared by 981.69% to $276.1 million in 2023, then tumbled by 85.93% to $38.8 million in 2024, then soared by 524.27% to $242.5 million in 2025.
  • Its last three reported values are $242.5 million in Q3 2025, $232.5 million for Q2 2025, and $48.1 million during Q1 2025.